Thank you, Mr. Chair.
When we were preparing for the receipt of the submissions, there were a lot of discussions that happened before we received them in terms of the requirements. For the safety, efficacy and quality of the vaccines, it was decided very early that we were not going to make any changes to those requirements, maintaining the same rigorous standards that we would for all vaccines.
What we did was find efficiencies in terms of the review processes. It still took the same number of hours to do the reviews, but there was less downtime and there were flexibilities on the administrative side provided to the company so they could provide, for example, what we call a rolling submission. As data became available, they could provide that data to us. We compressed the normal time for the review into a very short period of time.